ArticleBlood advances2020

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Theodore C Tarver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.